WO2007009208A1 - Poly(ethylene glocol) modified human gm-csf with increased biological activity - Google Patents
Poly(ethylene glocol) modified human gm-csf with increased biological activity Download PDFInfo
- Publication number
- WO2007009208A1 WO2007009208A1 PCT/CA2006/000885 CA2006000885W WO2007009208A1 WO 2007009208 A1 WO2007009208 A1 WO 2007009208A1 CA 2006000885 W CA2006000885 W CA 2006000885W WO 2007009208 A1 WO2007009208 A1 WO 2007009208A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- peg
- human
- molecule
- kda
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title claims abstract description 99
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims abstract description 99
- 230000004071 biological effect Effects 0.000 title description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 title description 2
- 239000005977 Ethylene Substances 0.000 title description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 77
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims abstract description 67
- 102000046157 human CSF2 Human genes 0.000 claims abstract description 64
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 14
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 210000000440 neutrophil Anatomy 0.000 claims description 11
- 150000001299 aldehydes Chemical class 0.000 claims description 7
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 17
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract description 10
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000010076 replication Effects 0.000 abstract description 2
- 230000032823 cell division Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000006320 pegylation Effects 0.000 description 14
- -1 poly(ethylene glycol) Polymers 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 229920001427 mPEG Polymers 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000001488 sodium phosphate Substances 0.000 description 7
- 229910000162 sodium phosphate Inorganic materials 0.000 description 7
- 235000011008 sodium phosphates Nutrition 0.000 description 7
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 208000004235 neutropenia Diseases 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 108010038379 sargramostim Proteins 0.000 description 6
- 229960002530 sargramostim Drugs 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000005251 capillar electrophoresis Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 108010032806 molgramostim Proteins 0.000 description 4
- 229960003063 molgramostim Drugs 0.000 description 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010073306 Exposure to radiation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- VXCHGLYSIOOZIS-GUBZILKMSA-N Pro-Ala-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 VXCHGLYSIOOZIS-GUBZILKMSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 101150039352 can gene Proteins 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011809 primate model Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108010056532 regramostim Proteins 0.000 description 3
- 229950006324 regramostim Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010001881 Alveolar proteinosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000006816 Neonatal Sepsis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 150000003999 cyclitols Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 238000002497 phase alternated rotation of magnetisation Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108010088880 plasmagel Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the instant invention relates to a chemical modification of granulocyte- macrophage colony-stimulating factor (GM-CSF), by which the chemical and/or physiological properties of GM-CSF can be changed.
- GM-CSF granulocyte- macrophage colony-stimulating factor
- Recombinant human GM-CSF is known in the art and used to treat several disorders including neutropenia following radiotherapy or chemotherapy. As with most cytokines, human GM-CSF has a short half-life in circulation, requiring repeated injections.. Additionally, recombinant human GM-CSF has been shown to be immunogenic and antigenic, leading to the generation of inhibitory antibodies.
- Regramostim produced in CHO cells, has the full-length native human GM-CSF peptide sequence, and has the most complete (closest to human) glycosylation profile. As a consequence of its full glycosylation, Regramostim has increased half-life but a significantly reduced bioactivity compared to other GM-CSF products (Hussein et al, 1995).
- Sargramostim (LeukineTM), produced in the yeast Saccharomyces cereviseae, differs from the native human GM-CSF amino acid sequence by virtue of a substitution of Leucine at position 23. This change ameliorates a protease degradation problem in the yeast production system (US 5,393,870). Even a single amino acid change, however, can be implicated in increased immunogenicity of proteins in general and is proposed as a causative factor in yeast GM-CSF immunogenicity in particular (Rini et al, 2005). Sargramostim, by virtue of its production in yeast, is somewhat glycosylated. As a consequence of its glycosylation, Sargramostim has significantly reduced bioactivity in vivo compared to non-glycosylated GM-CSF (Hussein et al, 1995).
- Molgramostim (LeucomaxTM), produced in E.coli, differs from the native human GM-CSF amino acid sequence by virtue of deletion of the six N-terminal amino acids, as well as the addition of an N-terminal methionine residue.
- Molgramostim As a bacterial protein product, Molgramostim is unglycosylated, contributing to its superior bioactivity compared to Regramostim ⁇ and Sargramostim (Hussein et al, 1995). Molgramostim's side-effect profile is claimed to be worse than that of Sargramostim (Dorr, 1993), but it is suggested that this is due to unnecessarily high doses of the more active non-glycosylated form.
- the observed activity may be the result of the cells reacting to exposure to radiation, lodination is a harsh treatment that often results in modification of a protein's secondary structure.
- lodination is a harsh treatment that often results in modification of a protein's secondary structure.
- Sherman et al teach the conjugation of 19 kDa PEG to human GM-CSF by p-Nitrophenyl Carbonate to produce mono-PEGylated and di-PEGylated human GM-CSF. Additionally, Sherman et al conjugated either a 5 kDa or 42 kDa PEG to human GM-CSF by a PEG aldehyde to produce a mono-PEGylated human GM-CSF. Sherman states that human GM-CSF is from Immunex, which produces Sargramostim (LeukineTM) in a yeast expression system. As described above, glycosylated GM-CSF behaves differently than non-glycosylated GM-CSF.
- DeFrees et al describe a site-directed PEGylated human GM-CSF prepared by expressing non-glycosylated GM-CSF in E. coli, followed by enzymatic GalNAc-glycosylation at specific serine and threonine residues, followed by enzymatic transfer of sialic acid conjugated with linear 2OkDa PEG to the introduced GaINAc residues (primarily at Ser 7 and Ser 9 ).
- a non-homogenous mixture of singly, doubly and triply-PEGylated GM-CSF was produced by this method, and neither in vitro nor in vivo experiments to demonstrate bioactivity or pharmacokinetic parameters were performed (DeFrees et al, 2006).
- Doherty et al created analogues of human GM-CSF engineered to contain additional cysteine residues, which were then PEGylated with cysteine-reactive 5kDa, 1OkDa, or 2OkDa linear PEG or 4OkDa branched PEG.
- the 5, 10 and 2OkDa PEG modifications did not substantially change the in vitro bioactivity of human GM-CSF, while the 4OkDa PEGylation decreased bioactivity.
- the PEGylated cysteine-bearing GM-CSFs demonstrated increased halflives in rats correlating with the size of the PEG molecules; since human GM-CSF does not function in rodents, no in vivo efficacy data was presented (Doherty et al, 2005).
- Bossard et al demonstrate the synthesis of human GM-CSF conjugated to a variety of activated PEG molecules, including 4OkDa branched mPEG, 3OkDa linear mPEG, and 2OkDa linear mPEG.
- the authors show how to prepare and purify PEG-GM-CSF conjugates, but simply claim that in vitro bioactivity of the conjugates has been demonstrated, without quantifying the bioactivity or even describing the assays used.
- no animal data are presented whatsoever. As such, there is no indication if PEGylated human GM-CSG has any activity in an animal.
- the present invention is a full length, non-glycosylated human GM-CSF having a single polyethylene glycol molecule covalently attached through an N-terminal amino acid.
- the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising human GM-CSF having a single polyethylene glycol molecule covalently attached through ah N-terminal amino acid.
- the present invention is the use of human GM-CSF having a single polyethylene glycol molecule covalently attached through an N-terminal amino acid to increase circulating neutrophils in a primate.
- FIG.1 shows capillary electrophoretic separation of human GM-CSF PEGylation reaction coupled to zero, one, two or three PEG molecules per protein.
- FIG. 2 shows a RP-HPLC tracing of purified monoPEGylated human GM- CSF.
- FIG. 3 shows a RF- HPLC analyses of tryptic peptide digests of A. GM-CSF and B. 20 kDa PEG-GM-CSF.
- FIG. 4 shows a GM-CSF dependent TF-1 cell proliferation
- Triangles 20 kDa PEG-GM-CSF; diamonds: NIBSC human GM-CSF standard; squares non-PEGylated GM-CSF.
- FIG. 5 shows rat serum concentrations of 20 kDa PEGylated GM-CSF (triangles) and nonPEGylated GM-CSF (squares).
- FIG. 6 shows absolute neutrophil count of monkeys administered 20 kD, 30 kD and 40 kD PEG-GM-CSF on days 1 and 7 post 6.00 cGy x-irradiation.
- FIG. 7 shows the serum concentration of 20 kD, 30 kD and 40 kD PEG- GM-CSF in the monkeys described in Fig 6.
- FIG. 8 shows DNA (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) sequences of GM-CSF. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
- human GM-CSF shall mean an isolated human granulocyte- macrophage colony stimulating factor polypeptide that does not have glycosylation groups attached. Specifically, a human GM-CSF polypeptide substantially having 127 amino acids and the amino acid sequence of mature human granulocyte-macrophage colony stimulating factor as described in US Patent No. 5,891,429 for example as shown in Figure 7.
- GM-CSF GM-CSF protein that is non-glycosylated and has a single PEG molecule on the N-terminal amino acid.
- N-terminal pegylated GM-CSF has significantly enhanced potency.
- human GM-CSF polypeptide examples include expression systems utilizing E. coli, assuming the human GM-CSF polypeptide is expressed as a mature GM- CSF polypeptide having substantially 127 amino acids.
- Alternate sources for human GM- CSF that may be used in the instant invention include human GM-CSF polypeptides isolated from mammalian or yeast expression system wherein the glycosylation groups are removed from the human GM-CSF polypeptide. Plant and insect cell expression systems may also be used to express human GM-CSF.
- PEG refers to poly(ethylene glycol) having a chemical formula HO(CH 2 )nCH 2 OH.
- blocking group as used herein is intended to imply a moiety which when covalently bound to a PEG terminus, is capable of preventing the attachment of an activating group to that terminus during the activation process.
- blocking groups include monomethoxypoly(ethylene glycol), usually abbreviated as mPEG, which contains an additional monomethoxy group at one end of the polymer (chemical formula CH 3 O - (CH 2 CH 2 O) n - CH 2 CH 2 OH).
- PEG-GM-CSF refers to granulocyte- macrophage colony-stimulating factor conjugated to poly(ethylene glycol) with a blocking group.
- the blocking group is part of the PEG molecule and ensures one PEG reacts with one GM-CSF molecule. Without the blocking group, PEG could react at both ends resulting in two GM-CSF molecules being cross-linked by one PEG molecule.
- the preferred molecular weight of the PEG is between about 20 kDa and about 50 kDa.
- the term "about” indicates that in. preparations of polyethylene glycol, some molecules will weigh more or less than the stated molecular weight.
- the mass mentioned before PEG-GM-CSF refers only to the mass of the polymer itself.
- 20 kDa PEG-GM-CSF refers to an average PEG molecular mass of 20 kiloDaltons.
- the total molecular mass of the PEG-GM-CSF would be the molecular mass of the PEG (20 kDa), plus the molecular mass of the human GM-CSF (14.5 kDa), for a total of 34.5 kDa.
- the PEG molecule is less than 20 kDa, then the PEG-GM-CSF is not likely to have a significant increase in half-life in circulation. If the PEG molecule is greater than 50 kDa, then PEG-GM-CSF has decreased biological activity, likely due to steric hindrance of the PEG molecule interfering with GM-CSF binding to its receptor.
- PEG PEG
- Nektar Therapeutics San Carlos, CA, US
- Enzon Pharmaceuticals Bridgewater, NJ, US
- Sigma-Aldrich Sunbio USA
- Sunbio USA Orinda, CA, US
- NOF Corporation NOF Corporation (Tokyo, Japan).
- PEG may be prepared, for example, as described in U.S. Pat. No. 5,428,128; U.S. Pat. No. 6,127,355; and U.S. Pat. No. 5,880,131. Description of PEGylation reaction
- the instant application contemplates a PEG molecule bound onto human GM-CSF via a N-terminal reactive group, specifically the alpha amine group at the N- terminus.
- PEG aldehyde is reacted with human GM-CSF under such conditions that a ' single molecule of PEG is attached preferentially to the' N- terminal amino acid of the human GM-CSF.
- PEG aldehyde is reacted with human GM-CSF via a reductive amination reaction in the presence of a reducing agent.
- the resulting secondary amine bond between the mPEG and human GM-CSF that is formed upon reduction is stable under physiological conditions.
- the site of attachment is at the alpha-terminal amine at the N-terminus of the human GM-CSF.
- the mPEG aldehyde is mPEG butyraldehyde reacted at pH 5 to 7.5 in the presence of sodium cyanobromohydride.
- chemistries may be used to chemically attach PEG molecules to the N-terminal amino acid.
- One alternative that may be used to form a terminal reactive group on monomethoxyPEG (MPEG) is tresyl chloride (2,2,2,-trifluoroethane-sulphonyl chloride), which creates a single free derivatisable OH group.
- tresyl chloride (2,2,2,-trifluoroethane-sulphonyl chloride)
- Activation of the hydroxyl group at the end of the polymer opposite to the terminal methoxy group is generally necessary to accomplish efficient protein PEGylation, with the aim being to make the derivatised PEG more susceptible to nucleophilic attack.
- the attacking nucleophile is usually the epsilon-amino group of a lysyl residue, but other amines can also react (e.g. the N-terminal alpha-amine or the ring amines of histidine) if conditions are favourable.
- site-specific PEGylation is achieved by introducing a "free" cysteine residue, i.e., a cysteine residue not involved in a disulfide bond, into a target protein using site-directed mutagenesis.
- the free cysteine residue serves as the attachment point for covalent modification of the protein with a cysteine- reactive PEG molecule.
- Attachment of the PEG molecule to the free cysteine residue is highly specific because most native cysteine residues in proteins participate in disulfide bonds and are not available for PEGylation using cysteine-reactive PEGs. PEGylation of the cysteine muteins yield a single monoPEGylated species modified at the free cysteine residue.
- PEG is attached to the GM-CSF polypeptide directly or without an intervening linker.
- PEG can also be attached to the N-terminal amino acid of GM-CSF polypeptides using a number of different intervening linkers that serve as a terminal reactive group.
- intervening linkers that serve as a terminal reactive group.
- U.S. Pat. No. 5,612,460 discloses urethane linkers for connecting polyethylene glycol to proteins.
- Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein or polypeptide by a linker can also be produced by reaction of proteins or polypeptides with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1 ,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-.rho.- nitrophenolcarbonate, and various MPEG-succinate derivatives.
- MPEG-succinimidylsuccinate MPEG activated with 1 ,1'-carbonyldiimidazole
- MPEG-2,4,5-trichloropenylcarbonate MPEG-.rho.- nitrophenolcarbonate
- MPEG-succinate derivatives A number of additional polyethylene glycol derivatives and reaction chemistries for attaching PEG to proteins and polypeptides are described in EP 0 714 402.
- the choice of chemical reaction used to attach the PEG to the N-terminal amino acid of human GM-CSF may affect the choice of the proportion of PEG molecules to GM-CSF molecules used in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally monoPEGylated GM- CSF polypeptides from the reaction mix.
- the method of obtaining the N-terminally monoPEGylated preparation i.e., separating this moiety from other PEGylated moieties if necessary
- Selective chemical modification at the N- terminus of the protein may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N- terminus) available for derivatization in a particular protein. Under the appropriate range of reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved. Purification and Confirmation of Identity of PEG-GM-CEF
- a polyethylene glycol-modified human GM-CSF may be purified from a reaction mixture by conventional methods which are used for purification of proteins, such as dialysis, salting-out, ultrafiltration, FPLC (fast protein liquid chromatography protocol), ion- exchange chromatography, gel chromatography and electrophoresis. Ion-exchange chromatography and FLPC are particularly effective in removing unreacted polyethylene glycol and human GM-CSF.
- a polyethylene glycol-modified human GM-CSF may also be purified from a reaction mixture by partitioning the PEG-GM-CSF in a PEG-containing aqueous biphasic system as described in US Patent No. 6,384,195. Testing in vitro
- the major forms of in vitro assay used to assess the direct effects of human GM- CSF include cell proliferation assays and assays that assess the ability of the molecule to induce colony formation in progenitor cells.
- Proliferation In proliferation assays, cells grow and divide in response to human GM- CSF. Proliferation may be measured directly by counting the cells (microscope or automated methods), or indirectly by measuring the uptake of radioactive compounds "such as tritiated thymidine, by the use of chromogenic dyes to quantitate total protein, or by measuring metabolic activity through the use of substrates that form coloured products upon reaction with cellular enzymes (including, but not limited to, the MTT assay and refinements thereof such as the XTT and WST-1 assays, and the Alamar Blue assay).
- radioactive compounds such as tritiated thymidine
- chromogenic dyes to quantitate total protein
- metabolic activity through the use of substrates that form coloured products upon reaction with cellular enzymes (including, but not limited to, the MTT assay and refinements thereof such as the XTT and WST-1 assays, and the Alamar Blue assay).
- GM-CSF The most common in vitro bioassay of GM-CSF, used to establish activity comparisons to WHO standard GM-CSF, is a standard cell proliferation assay (coluorimetric or tritiated thymidine incorporation) using the human growth factor-dependent cell line TF-1.
- Other cell lines that may be used to assay GM-CSF mediated proliferation include (bur are not limited to) AML-193 ; B6SUt-A ; BAC1.2F5 ; BCL1 ; Da ; FDCP 1 ; GF-D8 ; GM/SO ; IC-2 ; KG-1 ; MO7E ; NFS-60 ; PT-18 ; TALL-103 ; UT-7.
- GM-CSF Another test of human GM-CSF biological activity is the colony formation or clonogenic assay.
- GM-CSF dependent cells are grown in a viscous medium such as soft agar, methylcellulose, plasma gel or fibrin clots, which retards cell movement, allowing the formation of localized cell colonies:
- the activity of human GM- CSF is assayed by its ability to induce development of differentiated colonies of hematopoietic progenitor cells from bone marrow over period of 7 -14 days.
- This type of assay demonstrates the ability of human GM-CSF to appropriately determine the lineage along which colony-forming cells differentiate. By performing this assay in a dose- response format, specific activity of human GM-CSF can also be measured.
- Vivo Testing of PEG-GM-CSF In Vivo Testing of PEG-GM-CSF
- Animal models appropriate for such testing include, but are not limited to, humans, non-human primates, canines, and rodents (such as rabbits, " rats and mice). Furthermore, the animal models may be healthy, or reflect various disease states, such as diabetes or radiation sickness.
- GM-CSF In vivo testing of GM-CSF is also helpful in determining its effect on hematopoietic responses, dose response relationships and toxicities. Due to the species specificity of GM-CSF's effects, primate models are necessary for this type of in vivo
- healthy or irradiated monkeys are injected with GM-CSF and blood cell counts are monitored, including but not limited to circulating leukocytes, granulocytes, monocytes, neutrophils, platelets and erythrocytes.
- compositions of PEG-GM-CSF may consist of, but are not limited to, liquid or lyophilized preparations preferably suitable for subcutaneous or intravenous administration, and may also include alternate routes of administration including intramuscular, oral or inhalational.
- a lyophilized formulation for PEG-GM-CSF may include a stabilizer to inhibit denaturation of the PEG-GM-CSF during lyophilization and rehydration, and optionally a buffer, a tonicifying agent and a preservative. However, a buffer and tonicifying agent may be included in the solution utilized to rehydrate the lyophilized PEG-GM-CSF.
- a liquid, ready for use, PEG-GM-CSF formulation may include a stabilizer to inhibit denaturation of the PEG-GM-CSF during storage or when exposed to shear forces, a tonicifying agent, and optionally a buffer and optionally a preservative if the formulation is for multiple uses.
- stabilizers include, sugars, amino acids, organic salts, inorganic salts, diluents, buffering agents, surfactants and preservatives.
- Stabilizers may further include, human serum albumin, bovine serum albumin and gelatin.
- Tonicifying agents may include sugars and organic salts.
- Sugars may include, but are not limited to, monosaccharides such as xylose, mannose, glucose and fructose, disaccharides such as trehalose, lactose, maltose and sucrose, trisaccharides such as raffinose, polysaccharides such as dextran, sugar alcohols such as mannitol, sorbitol and glycerol, and cyclitols such as inositol.
- Amino acids may include but are not limited to glycine, alanine and lysine.
- Inorganic salts may include but are not limited to sodium chloride, potassium chloride, calcium chloride, dibasic sodium phosphate, monobasic sodium phosphate potassium phpsphate and sodium hydrogencarbonate.
- Organic salts include but are not limited to sodium citrate, potassium citrate and sodium acetate.
- Buffering agents may include, but are not limited to, Tris, phosphate bufferand citrate buffer.
- Surfactants may include, but are not limited to polysorbate 80 and polysorbate 20.
- Diluents may include, but are not limited to USP Water for Injection or sterile saline such as phosphate buffered saline.
- Preservatives may include, but are not limited to, benzyl alcohol, chlorobutanol, methylparaben, propylparaben, phenol, m-cresol, benzalkonium chloride, benzethonium chloride, phenoxyethanol, phenylethyl alcohol, chlorhexidine, benzoic acid, phenylmercuric salts and thimerosal. Use in humans
- PEG-GM-CSF may be used in humans for the same indications as GM- CSF for treatment of patients requiring increased proliferation of white blood cells, often with diseases characterized by neutropenias, aberrant blood cell maturation or reduced leukocyte production.
- An important clinical application of GM-CSF is treatment of neutropenia following chemotherapy, radiation therapy and bone marrow transplantation. Such therapy can help counter related predispositions to infection and hemorrhage.
- Indications include:
- PEG-GM-CSF may be used to enhance tolerance to cytotoxic drugs, such as chemotherapeutic agents, allowing for increased dosing.
- PEG-GM-CSF may be used to activate resting cancerous cells, making them more susceptible to chemotherapy.
- PEG-GM-CSF may also be used to treat Crohn's disease, as a vaccine adjuvant (5,679,356), as a treatment for neonatal sepsis, to lower cholesterol levels, as a treatment for radiation exposure, and as a treatment for alveolar proteinosis (6,019,965),
- PEG-GM-CSF may be used to modulate host defences against infectious disease, including bacterial/ and fungal infections; it may also be used as an adjunctive agent with treatments for fungal and mycobacterial infections.
- PEG-GM-CSF may be used to combat treatment-related neutropenia, as a prophylaxis and treatment for opportunistic infections, as an enhancer of retroviral treatments, and to reduce HlV expression.
- PEG-GM-CSF may furthermore be used to modulate host defences for improved anti-tumour or leukemic cell activity.
- PEG-GM-CSF including oral and mouthwash formulations, may also be used to treat complications of chemotherapy such as mucositis, stomatitis and diarrhea. Wound healing may be promoted by topical or intradermal PEG-GM-CSF.
- PEG-GM-CSF uses in humans may also be considered to include combinations of PEG-GM-CSF with other growth factors that have synergistic effects including but not limited to G-CSF, IL-6, lL-5, IL-3, MMF, SCF, Meg-CSF, IL-4, erythropoietin, IL-1 , IL-2, interferon-alpha, BCDF and TNF.
- AAA amino acid analysis
- AEX anion-exchange chromatography
- ANC absolute neutrophil count
- CE capillary electrophoresis
- HPLC high-performance liquid chromatography
- MALDI-MS matrix-assisted laser desorption ionization mass spectrometry
- NIBSC National Institute for Biological Standards and Control
- PEG poly(ethylene glycol); PK, pharmacokinetic;
- RP-HPLC reversed-phase high-performance liquid chromatography;
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis;
- SEC size-exclusion chromatography.
- Materials Acetonitrile, HPLC grade LeucotropinTM (Cangene's GM-CSF) DL-lysine Mannitol MiIIi-Q water
- LEUCOTROPINTM (200 mg total) was produced at Cangene Corporation at 2 mg/ml in 10 mM sodium phosphate, 150 mM NaCI pH 7.0. LEUCOTROPINTM had previously been characterized for identity (Western blot), concentration (A 2 so), purity (anion exchange, size- exclusion chromatography), and biological potency (TF-1/MTT bioassay; data not shown). LEUCOTROPINTM was dialyzed using SnakeSkin ® dialysis tubing, 3500 MWCO (Pierce Endogen) in 10 mM sodium phosphate buffer, pH 7.0 for 48 h at 4°C prior to conjugation, with buffer changed twice.
- SnakeSkin ® dialysis tubing 3500 MWCO (Pierce Endogen) in 10 mM sodium phosphate buffer, pH 7.0 for 48 h at 4°C prior to conjugation, with buffer changed twice.
- the conjugation reaction was carried out at 4°C with stirring in 10 mM sodium phosphate buffer, pH 7.0 plus 20 mM sodium cyanoborohydride at a 5:1 mol ratio of 20 kDa PEG-butyraldehyde:protein. Reaction progress was monitored by size-exclusion chromatography. The reaction was quenched with an excess of DL-lysine (Sigma) after 18 hr.
- Reaction product was characterized by capillary electrophoresis (CE) on a Beckman P/ACE System 5010 using a 57 cm, 75 ⁇ m I.D., 375 ⁇ m O. D. eCAPTM silica capillary wound in an eCAPTM capillary cartridge, 100 x 200 urn aperture. Buffer was 100 mM sodium phosphate pH 8.3 run at 8.0 kV; UV absorbance was monitored at 200 nm. Four peaks were observed with CE ( Figure 1), corresponding to non-PEGylated human GM-CSF and human GM-CSF with 1 , 2, or 3 molecules of PEG attached. Purification and Confirmation of Identity of monoPEGylated GM-CSF
- Reaction product was dialyzed using SnakeSkin ® dialysis tubing, 3500 MWCO (Pierce Endogen) in 20 mM sodium phosphate pH 8.0 for 48 h at 4 0 C, changing buffer twice.
- the dialyzed PEGylation reaction product was purified on an AKTA Explorer FPLC system equipped with a 20 ml XK 16/10 column packed with Q Sepharose FF resin and a 50 ml Superloop.
- Elution buffer A was 20 mM sodium phosphate pH 8.0
- Buffer B was 20 mM sodium phosphate pH 8.0 plus 500 mM NaCI.
- Sample was eluted using a linear AB gradient from 0 to 225 mM NaCI.
- Fractions were analyzed by SDS-PAGE. Fractions containing only GM-CSF with a single PEG chain per molecule (;.e., monoPEGylated GM-CSF) were pooled and concentrated in Centricon Plus-20 ultracentrifugal filters (Millipore). A buffer exchange of PEG-GM-CSF was conducted by passing 10 mM sodium phosphate, 40 mM NaCI, 30 mg/ml mannitol pH 7.4 through Centricon Plus-20 centrifugal filter devices. The concentration of protein was obtained by measuring absorbance at 280 nm (A 2 so) and calculated using the molar extinction coefficient of 14180 M "1 cm "1 (derived from the amino acid composition of GM-CSF).
- Sample was diluted to 0.5 mg protein/ml final concentration with 10 mM sodium phosphate, 40 mM NaCI, 30 mg/ml mannitol pH 7.4.
- PEG-GM-CSF was subjected to a final 0.2 um sterile filtration using a 25 mm HT Tuffryn ® syringe filter (Pall Scientific), deposited in 1 ml aliquots into 3 ml sterile borosilicate vials (Comar), stoppered, capped and stored at -80 0 C.
- a sample from the fill lot was tested for endotoxin levels using the limulus amoebocyte lysate assay and was found to contain less than 25 endotoxin units/ml, indicating that samples were sterile and pyrogen-free.
- Final protein concentration of purified monoPEGylated PEG-GM-CSF was determined by UV absorbance at 280 nm and quantitative amino acid analysis on a Beckman 6300 high performance analyzer using System Gold software. Norleucine was added as an internal standard to all samples analyzed by amino acid analysis, and samples were hydrolyzed in 6 N HCI containing 0.1% phenol for 1 hr at 160 0 C, dried under vacuum and re-dissolved in 200 Dl of running buffer.
- GM-CSF and PEG-GM-CSF were subjected to trypsin digestion and analysis by reversed-phase HPLC to construct peptide maps, in order to determine the site of monoPEGylation.
- Either GM-CSF or the PEG-GM-CSF conjugate were buffer exchanged to 1 mg/ml protein concentration in 500 mM Tris buffer, pH 8.1.
- TPCK-trypsin (0.25 mg/ml in 1 mM HCI solution) (Worthington Enzymes) was added for a final 1 :25 ratio (w/w) of enzyme:protein and incubated at 37 0 C in 0.5 M Tris, pH 8.1.
- the site of PEG attachment on PEG-GM- CSF was determined using a combination of reversed-phase HPLC analysis and purification, mass spectrometry, and N-terminal peptide sequencing. Trypsin-digested sample was purified by reversed-phase chromatography and fractions corresponding to peptide peaks were collected and dried in a SpeedVac. One peak appeared in the digested PEG-GM-CSF sample that did not appear in the digested GM-CSF sample ( Figure 3).
- MALDI-MS QStar XL MALDI qTOF (Applied Biosystems) dihydroxybenzoic acid (DHB) matrix
- DLB dihydroxybenzoic acid
- the PEGylated peptide peak (obtained from the appropriate RP-HPLC fraction) from the trypsin digest of PEG-GM-CSF was subjected to five cycles of N- terminal Edman sequencing.
- the obtained amino acid sequence of Pro-Ala-Arg (PAR) in the PEGylated peptide corresponds to residues 2-4 of GM-CSF (data not shown). There are no regions in the sequence of GM-CSF other than at positions 2-4 that contain the PAR sequence, suggesting that PEGylation occurred on the tryptic peptide 1 AIa-PrO-AIa- Arg 4 ( 1 APAR 4 ).
- the APAR peptide Since the conjugation chemistry employed is specific to primary amino groups at the conditions used, the APAR peptide would only have a single possible site for PEG attachment, at the alpha-amine on the N-terminus. Because the N-terminus of the APAR peptide is also the N-terminus of the full-length GM-CSF molecule, we conclude that, in the monoPEGylated sample obtained, PEGylation occurred substantially at the N- terminus of the full-length GM-CSF protein sequence.
- Assay media was RPMI-1640 plus 0.001 mg/ml insulin, 0.001 mg/ml transferrin, 0.1 Omol/ml 2-mercaptoethanol, 0.02 mg/ml of gentamicin.
- TF-1 cells were added to all wells and incubated at a final well concentration of about 2.67X10 5 cells/ml in a 96-well tissue culture plate for 72 hr at 37 DC, 5% CO 2 . After 72 h incubation, one duplicate plate received 50 Dl of 4 mg/ml MTT (a tetrazolium salt) per well followed by incubation for 3 hr at 37 GC, 5% CO 2 .
- MTT a tetrazolium salt
- Plates were then centrifuged at 1770 g for 15 minutes, supematants were aspirated and 50 Dl of isopropanol were added to each well. Plates were shaken for 5 minutes and absorbance, which increases with cell proliferation in this assay, was read at 595 nm on a 96-well plate reader. The other duplicate plate was placed on ice to minimize additional cell proliferation, 30 Dl aliquots were removed and added to 30 Dl of Trypan blue stain. Live cells were counted on a hemacytometer to determine live cell concentration from each well.
- the log dose-response curve for the 1st International Reference Standard was fit using a four-parameter logistic model and estimates of the curve fit parameters obtained. The upper and lower asymptotes, plus the slope factor were then fixed prior to fitting the remaining sample dose-response curves. From the curve fits, estimates of EC50 (the concentration of growth factor that results in 50% maximum response) were obtained. The ratio of the EC50 value obtained for the Reference standard divided by the EC50 value for each Test Sample gives a relative potency that is then multiplied by the assigned potency of the Reference Standard to obtain a potency estimate for each Test Sample.
- Cangene's PEGylated versions of GM-CSF exhibit significantly enhanced potency (5.4- 6.7 fold) over the non-PEGylated Leucotropin and the 1st International Reference Standard. Similar enhancement was seen in both the MTT bioassay and direct cell counting methods for determining cell proliferation. There was no significant difference in measured potency between the 2OkDa, 3OkDa and 4OkDa PEG-GM-CSF.
- animals treated with the 3OkDa and 40 kDa PEG-GM-CSF demonstrated an ANC recovery comparable to controls that were treated with supportive care only.
- the rate of neutrophil loss was slowed to 0 from day 3 to 5 ( Figure 6, squares), relative to negative control monkeys receiving autologous serum ( Figure 6, rectangle).
- Significant improvement (about 10x increase) in ANC was observed from day 8 to 11 following the second PEG-GM-CSF dosing, on day 7 ( Figure 6).
- the recovery of animals treated with the 20 kD PEG-GM-CSF is surprising given the concentration of PEG-GM-CSF in the serum.
- the serum levels of 40 kD PEG-GM-CSF reached about 650,000 pg/ml compared to about 280,000 ⁇ g/ml for the 30 kD PEG-GM-CSF and about 250,000 pg/ml for the 30 kD PEG-GM-CSF ( Figure 7).
- the serum levels for the 30 kD and 40 kD PEG-GM-CSF molecule appeared to remain at their peak for about 2 to 3 days after the first injection, whereas the levels of 20 kDa PEG-GM-CSF peaked on the day of injection and rapidly decreased.
- GM-CSF is a key proinflammatory cytokine.
- reactions at GM-CSF injection sites such as swelling, redness and tenderness, are common side effects.
- Subcutaneous injection of GM-CSF or 20, 30, or 4OkDa PEG-GM-CSF resulted in localized inflammation in a primate model of myelosuppression.
- the 2OkDa PEG-GM-CSF produced mild inflammation that was easily treatable with antihistamine (diphenhydramine), the 30 and 40 kDa PEG-GM-CSF molecules caused inflammation that was more severe.
- the unexpected finding suggests that 2OkDa PEG- GM-CSF is the optimal choice of PEGylated GM-CSF.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a full length, non-glycosylated human GM-CSF polypeptide having a single polyethylene glycol molecule covalently attached through an N-terminal amino acid. According to the present invention, the human GM-CSF polypeptide with the attached polyethylene glycol molecule has an unexpectedly increased ability to stimulate the replication of cells in culture compared to the non-modified GM-CSF molecule. This increased ability to stimulate cell division in culture is reflected in neutrophil-increasing activity in an animal model.
Description
Poly(ethylene glocol) Modified Human GM-CSF with Increased Biological Activity
PRIOR APPLICATION INFORMATION
This application claims the benefit of US Provisional Application 60/686,430, filed June 2, 2005. FIELD OF THE INVENTION
The instant invention relates to a chemical modification of granulocyte- macrophage colony-stimulating factor (GM-CSF), by which the chemical and/or physiological properties of GM-CSF can be changed.
BACKGROUND OF THE INVENTION
Recombinant human GM-CSF is known in the art and used to treat several disorders including neutropenia following radiotherapy or chemotherapy. As with most cytokines, human GM-CSF has a short half-life in circulation, requiring repeated injections.. Additionally, recombinant human GM-CSF has been shown to be immunogenic and antigenic, leading to the generation of inhibitory antibodies.
The prior art teaches three commercial varieties of recombinant human GM-CSF:
1. Regramostim, produced in CHO cells, has the full-length native human GM-CSF peptide sequence, and has the most complete (closest to human) glycosylation profile. As a consequence of its full glycosylation, Regramostim has increased half-life but a significantly reduced bioactivity compared to other GM-CSF products (Hussein et al, 1995).
2. Sargramostim (Leukine™), produced in the yeast Saccharomyces cereviseae, differs from the native human GM-CSF amino acid sequence by virtue of a substitution of Leucine at position 23. This change ameliorates a protease degradation problem in the yeast production system (US 5,393,870). Even a single amino acid change, however, can be implicated in increased immunogenicity of proteins in general and is proposed as a causative factor in yeast GM-CSF immunogenicity in particular (Rini et al, 2005). Sargramostim, by virtue of its production in yeast, is somewhat glycosylated. As a consequence of its glycosylation, Sargramostim has significantly reduced bioactivity in vivo compared to non-glycosylated GM-CSF (Hussein et al, 1995).
3. Molgramostim (Leucomax™), produced in E.coli, differs from the native human GM-CSF amino acid sequence by virtue of deletion of the six N-terminal amino acids, as well as the addition of an N-terminal methionine residue. As a bacterial protein product, Molgramostim is unglycosylated, contributing to its superior bioactivity compared
to Regramostim ■ and Sargramostim (Hussein et al, 1995). Molgramostim's side-effect profile is claimed to be worse than that of Sargramostim (Dorr, 1993), but it is suggested that this is due to unnecessarily high doses of the more active non-glycosylated form. In light of different levels of immunogenicity seen in humans with two non-glycosylated GM- CSF products with differing sequences, it is suggested that even a single amino acid change from the native human sequence in non-glycosylated GM-CSF can influence immunogenicity; Molgramostim has much more significant differences from the native human sequence than this, that may account for its observed levels of immunogenicity (Wadhwa, 1999).
Such prior art clearly demonstrates that a glycosylated GM-CSF produced in a yeast or mammalian system behaves differently than a non-glycosylated truncated GM-CSF produced in E. coli, both in culture and in clinical trials.
Several groups have demonstrated that PEGylation of cytokines improves the pharmacokinetic profile (and thus activity) and reduces immunogenicity by shielding immunogenic epitopes from immune scrutiny. The prior art also teaches PEGylated human GM-CSF. Specifically, US Pat No 6,384,195 teaches a human GM-CSF protein that is PEGylated at multiple sites with PEG molecules in the range of 5 to 6 kDa molecular weight. There is no teaching as to the source of the human GM-CSF (mammalian, yeast or bacteria). Finally, it is clear that the biological activity that was noted with the PEGylated GM-CSF is from a radiolabeled (iodinated) human GM-CSF protein. As such, the observed activity may be the result of the cells reacting to exposure to radiation, lodination is a harsh treatment that often results in modification of a protein's secondary structure. Thus, any results described in the '195 patent are difficult to interpret as being specific to PEGylation of the GM-CSF protein.
Sherman et al teach the conjugation of 19 kDa PEG to human GM-CSF by p-Nitrophenyl Carbonate to produce mono-PEGylated and di-PEGylated human GM-CSF. Additionally, Sherman et al conjugated either a 5 kDa or 42 kDa PEG to human GM-CSF by a PEG aldehyde to produce a mono-PEGylated human GM-CSF. Sherman states that human GM-CSF is from Immunex, which produces Sargramostim (Leukine™) in a yeast expression system. As described above, glycosylated GM-CSF behaves differently than non-glycosylated GM-CSF. Additionally, Sherman discloses PEGylated murine GM-CSF. However, human GM-CSF does not bind to mouse cells and murine GM-CSF does not bind to human cells, and there is no cross-reactivity between these GM-CSF's.
Additionally, murine GM-CSF behaves differently in a mouse than human GM-CSF behaves in humans (O'Reilly, R., J., et al, 1990).
Publications by Malik, F. et al 1992 and Knusli, C et al 1992, describe a PEGylated human GM-CSF protein having conserved biological activity compared to non- PEGylated GM-CSF in stimulating replication of GM-CSF responsive cells. Both Malik and Knusli publications describe the recombinant human GM-CSF as obtained "from Biogen, Amgen or Hoechst". However, there is no description of the sequence of the human GM-CSF used, or its glycosylation state. Neither Malik nor Knusli describe the molecular weight of the PEG molecule that was conjugated to human GM-CSF or the position(s) of the PEG molecule. And finally, neither Malik nor Knusli isolated their PEGylated GM-CSF protein, and thus all reported test results are for a mixture of non- PEGylated GM-CSF and GM-CSF PEGylated to various degrees. Furthermore, the effects of a given cytokine in vivo do not necessarily reflect the in vitro situation (O'Reilly, R., J., et al, 1990).
DeFrees et al describe a site-directed PEGylated human GM-CSF prepared by expressing non-glycosylated GM-CSF in E. coli, followed by enzymatic GalNAc-glycosylation at specific serine and threonine residues, followed by enzymatic transfer of sialic acid conjugated with linear 2OkDa PEG to the introduced GaINAc residues (primarily at Ser7 and Ser9). However, a non-homogenous mixture of singly, doubly and triply-PEGylated GM-CSF was produced by this method, and neither in vitro nor in vivo experiments to demonstrate bioactivity or pharmacokinetic parameters were performed (DeFrees et al, 2006).
Doherty et al created analogues of human GM-CSF engineered to contain additional cysteine residues, which were then PEGylated with cysteine-reactive 5kDa, 1OkDa, or 2OkDa linear PEG or 4OkDa branched PEG. The 5, 10 and 2OkDa PEG modifications did not substantially change the in vitro bioactivity of human GM-CSF, while the 4OkDa PEGylation decreased bioactivity. The PEGylated cysteine-bearing GM-CSFs demonstrated increased halflives in rats correlating with the size of the PEG molecules; since human GM-CSF does not function in rodents, no in vivo efficacy data was presented (Doherty et al, 2005).
In US Patent Application 20060036080, Bossard et al demonstrate the synthesis of human GM-CSF conjugated to a variety of activated PEG molecules, including 4OkDa branched mPEG, 3OkDa linear mPEG, and 2OkDa linear mPEG. The
authors show how to prepare and purify PEG-GM-CSF conjugates, but simply claim that in vitro bioactivity of the conjugates has been demonstrated, without quantifying the bioactivity or even describing the assays used. Moreover, no animal data are presented whatsoever. As such, there is no indication if PEGylated human GM-CSG has any activity in an animal. SUMMARY OF THE INVENTION
In a first aspect the present invention is a full length, non-glycosylated human GM-CSF having a single polyethylene glycol molecule covalently attached through an N-terminal amino acid.
In another aspect the present invention is a pharmaceutical composition comprising human GM-CSF having a single polyethylene glycol molecule covalently attached through ah N-terminal amino acid.
In another aspect the present invention is the use of human GM-CSF having a single polyethylene glycol molecule covalently attached through an N-terminal amino acid to increase circulating neutrophils in a primate. BRIEF DESCRIPTION OF THE DRAWINGS
FIG.1 shows capillary electrophoretic separation of human GM-CSF PEGylation reaction coupled to zero, one, two or three PEG molecules per protein.
FIG. 2 shows a RP-HPLC tracing of purified monoPEGylated human GM- CSF.
FIG. 3 shows a RF- HPLC analyses of tryptic peptide digests of A. GM-CSF and B. 20 kDa PEG-GM-CSF.
FIG. 4 shows a GM-CSF dependent TF-1 cell proliferation Triangles: 20 kDa PEG-GM-CSF; diamonds: NIBSC human GM-CSF standard; squares non-PEGylated GM-CSF.
FIG. 5 shows rat serum concentrations of 20 kDa PEGylated GM-CSF (triangles) and nonPEGylated GM-CSF (squares).
FIG. 6 shows absolute neutrophil count of monkeys administered 20 kD, 30 kD and 40 kD PEG-GM-CSF on days 1 and 7 post 6.00 cGy x-irradiation.
FIG. 7 shows the serum concentration of 20 kD, 30 kD and 40 kD PEG- GM-CSF in the monkeys described in Fig 6.
FIG. 8 shows DNA (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) sequences of GM-CSF.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Description/definition of GM-CSF
The term "human GM-CSF" shall mean an isolated human granulocyte- macrophage colony stimulating factor polypeptide that does not have glycosylation groups attached. Specifically, a human GM-CSF polypeptide substantially having 127 amino acids and the amino acid sequence of mature human granulocyte-macrophage colony stimulating factor as described in US Patent No. 5,891,429 for example as shown in Figure 7.
As discussed below, described herein is a full-length GM-CSF protein that is non-glycosylated and has a single PEG molecule on the N-terminal amino acid. As discussed below, the N-terminal pegylated GM-CSF has significantly enhanced potency.
The prior art teaches many methods to produce human GM-CSF. One example is US Patent Nos. 5,200,327 and 5,641,663, which describe a transgenic Streptomyces expression system wherein synthetic DNA coding for human GM-CSF polypeptide was created following the codon usage of Streptomyces; that is, codons with C or G in the third position. The gene could be the natural cDNA sequence for GM-CSF, or any other DNA sequence encoding GM-CSF, with either Streptomyces codon usage, or any other biased or completely random codon usage.
Other sources of human GM-CSF polypeptide include expression systems utilizing E. coli, assuming the human GM-CSF polypeptide is expressed as a mature GM- CSF polypeptide having substantially 127 amino acids. Alternate sources for human GM- CSF that may be used in the instant invention include human GM-CSF polypeptides isolated from mammalian or yeast expression system wherein the glycosylation groups are removed from the human GM-CSF polypeptide. Plant and insect cell expression systems may also be used to express human GM-CSF. Source of PEG
The term "PEG" refers to poly(ethylene glycol) having a chemical formula HO(CH2)nCH2OH. The term "blocking group" as used herein is intended to imply a moiety which when covalently bound to a PEG terminus, is capable of preventing the attachment of an activating group to that terminus during the activation process. Examples of blocking groups include monomethoxypoly(ethylene glycol), usually abbreviated as mPEG, which contains an additional monomethoxy group at one end of the polymer (chemical formula CH3O - (CH2 CH2O)n - CH2 CH2 OH). Therefore, PEG-GM-CSF refers to granulocyte- macrophage colony-stimulating factor conjugated to poly(ethylene glycol) with a blocking
group. The blocking group is part of the PEG molecule and ensures one PEG reacts with one GM-CSF molecule. Without the blocking group, PEG could react at both ends resulting in two GM-CSF molecules being cross-linked by one PEG molecule.
The preferred molecular weight of the PEG is between about 20 kDa and about 50 kDa. The term "about" indicates that in. preparations of polyethylene glycol, some molecules will weigh more or less than the stated molecular weight. The mass mentioned before PEG-GM-CSF refers only to the mass of the polymer itself. For example, "20 kDa PEG-GM-CSF" refers to an average PEG molecular mass of 20 kiloDaltons. The total molecular mass of the PEG-GM-CSF would be the molecular mass of the PEG (20 kDa), plus the molecular mass of the human GM-CSF (14.5 kDa), for a total of 34.5 kDa. If the PEG molecule is less than 20 kDa, then the PEG-GM-CSF is not likely to have a significant increase in half-life in circulation. If the PEG molecule is greater than 50 kDa, then PEG-GM-CSF has decreased biological activity, likely due to steric hindrance of the PEG molecule interfering with GM-CSF binding to its receptor.
Commercial sources of PEG include Nektar Therapeutics (San Carlos, CA, US), Enzon Pharmaceuticals (Bridgewater, NJ, US), Sigma-Aldrich, Sunbio USA (Orinda, CA, US), NOF Corporation (Tokyo, Japan). PEG may be prepared, for example, as described in U.S. Pat. No. 5,428,128; U.S. Pat. No. 6,127,355; and U.S. Pat. No. 5,880,131. Description of PEGylation reaction
The instant application contemplates a PEG molecule bound onto human GM-CSF via a N-terminal reactive group, specifically the alpha amine group at the N- terminus. In a preferred embodiment, PEG aldehyde is reacted with human GM-CSF under such conditions that a' single molecule of PEG is attached preferentially to the' N- terminal amino acid of the human GM-CSF. Preferentially, PEG aldehyde is reacted with human GM-CSF via a reductive amination reaction in the presence of a reducing agent. The resulting secondary amine bond between the mPEG and human GM-CSF that is formed upon reduction is stable under physiological conditions. The site of attachment is at the alpha-terminal amine at the N-terminus of the human GM-CSF. In a preferred embodiment, the mPEG aldehyde is mPEG butyraldehyde reacted at pH 5 to 7.5 in the presence of sodium cyanobromohydride.
Alternative chemistries may be used to chemically attach PEG molecules to the N-terminal amino acid. One alternative that may be used to form a terminal reactive group on monomethoxyPEG (MPEG) is tresyl chloride (2,2,2,-trifluoroethane-sulphonyl
chloride), which creates a single free derivatisable OH group. Activation of the hydroxyl group at the end of the polymer opposite to the terminal methoxy group is generally necessary to accomplish efficient protein PEGylation, with the aim being to make the derivatised PEG more susceptible to nucleophilic attack. The attacking nucleophile is usually the epsilon-amino group of a lysyl residue, but other amines can also react (e.g. the N-terminal alpha-amine or the ring amines of histidine) if conditions are favourable. In an alternate embodiment, site-specific PEGylation is achieved by introducing a "free" cysteine residue, i.e., a cysteine residue not involved in a disulfide bond, into a target protein using site-directed mutagenesis. The free cysteine residue serves as the attachment point for covalent modification of the protein with a cysteine- reactive PEG molecule. Attachment of the PEG molecule to the free cysteine residue is highly specific because most native cysteine residues in proteins participate in disulfide bonds and are not available for PEGylation using cysteine-reactive PEGs. PEGylation of the cysteine muteins yield a single monoPEGylated species modified at the free cysteine residue.
The above examples generally teach chemistries wherein the PEG is attached to the GM-CSF polypeptide directly or without an intervening linker. PEG can also be attached to the N-terminal amino acid of GM-CSF polypeptides using a number of different intervening linkers that serve as a terminal reactive group. For example, U.S. Pat. No. 5,612,460 discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein or polypeptide by a linker can also be produced by reaction of proteins or polypeptides with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1 ,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-.rho.- nitrophenolcarbonate, and various MPEG-succinate derivatives. A number of additional polyethylene glycol derivatives and reaction chemistries for attaching PEG to proteins and polypeptides are described in EP 0 714 402.
The choice of chemical reaction used to attach the PEG to the N-terminal amino acid of human GM-CSF may affect the choice of the proportion of PEG molecules to GM-CSF molecules used in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally monoPEGylated GM- CSF polypeptides from the reaction mix. The method of obtaining the N-terminally monoPEGylated preparation (i.e., separating this moiety from other PEGylated moieties if
necessary) may be by purification of the N-terminally PEGylated material from a population of PEGylated protein molecules. Selective chemical modification at the N- terminus of the protein may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N- terminus) available for derivatization in a particular protein. Under the appropriate range of reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved. Purification and Confirmation of Identity of PEG-GM-CEF
A polyethylene glycol-modified human GM-CSF, namely chemically modified protein according to the present invention, may be purified from a reaction mixture by conventional methods which are used for purification of proteins, such as dialysis, salting-out, ultrafiltration, FPLC (fast protein liquid chromatography protocol), ion- exchange chromatography, gel chromatography and electrophoresis. Ion-exchange chromatography and FLPC are particularly effective in removing unreacted polyethylene glycol and human GM-CSF. A polyethylene glycol-modified human GM-CSF may also be purified from a reaction mixture by partitioning the PEG-GM-CSF in a PEG-containing aqueous biphasic system as described in US Patent No. 6,384,195. Testing in vitro
In vitro testing of recombinant and/or modified cytokines, such as PEG-GM- CSF, is typically performed to establish the specific activity and predict pharmacological effects. The major forms of in vitro assay used to assess the direct effects of human GM- CSF include cell proliferation assays and assays that assess the ability of the molecule to induce colony formation in progenitor cells.
In proliferation assays, cells grow and divide in response to human GM- CSF. Proliferation may be measured directly by counting the cells (microscope or automated methods), or indirectly by measuring the uptake of radioactive compounds "such as tritiated thymidine, by the use of chromogenic dyes to quantitate total protein, or by measuring metabolic activity through the use of substrates that form coloured products upon reaction with cellular enzymes (including, but not limited to, the MTT assay and refinements thereof such as the XTT and WST-1 assays, and the Alamar Blue assay). The most common in vitro bioassay of GM-CSF, used to establish activity comparisons to WHO standard GM-CSF, is a standard cell proliferation assay (coluorimetric or tritiated thymidine incorporation) using the human growth factor-dependent cell line TF-1. Other cell lines that may be used to assay GM-CSF mediated proliferation include (bur are not
limited to) AML-193 ; B6SUt-A ; BAC1.2F5 ; BCL1 ; Da ; FDCP 1 ; GF-D8 ; GM/SO ; IC-2 ; KG-1 ; MO7E ; NFS-60 ; PT-18 ; TALL-103 ; UT-7.
- Another test of human GM-CSF biological activity is the colony formation or clonogenic assay. In this type of assay, GM-CSF dependent cells are grown in a viscous medium such as soft agar, methylcellulose, plasma gel or fibrin clots, which retards cell movement, allowing the formation of localized cell colonies: The activity of human GM- CSF is assayed by its ability to induce development of differentiated colonies of hematopoietic progenitor cells from bone marrow over period of 7 -14 days. This type of assay demonstrates the ability of human GM-CSF to appropriately determine the lineage along which colony-forming cells differentiate. By performing this assay in a dose- response format, specific activity of human GM-CSF can also be measured. In Vivo Testing of PEG-GM-CSF
In vivo testing of PEG - GM-CSF is performed to demonstrate its pharmacokinetic and biodistribution characteristics. Animal models appropriate for such testing include, but are not limited to, humans, non-human primates, canines, and rodents (such as rabbits," rats and mice). Furthermore, the animal models may be healthy, or reflect various disease states, such as diabetes or radiation sickness.
In vivo testing of GM-CSF is also helpful in determining its effect on hematopoietic responses, dose response relationships and toxicities. Due to the species specificity of GM-CSF's effects, primate models are necessary for this type of in vivo
> testing. Typically, healthy or irradiated monkeys are injected with GM-CSF and blood cell counts are monitored, including but not limited to circulating leukocytes, granulocytes, monocytes, neutrophils, platelets and erythrocytes.
Both rodent and rat models and human models have been used to assess GM-CSF's effects on wound healing, with both healthy and diseased subjects. Pharmaceutical formulations
Pharmaceutical formulations of PEG-GM-CSF may consist of, but are not limited to, liquid or lyophilized preparations preferably suitable for subcutaneous or intravenous administration, and may also include alternate routes of administration including intramuscular, oral or inhalational. A lyophilized formulation for PEG-GM-CSF may include a stabilizer to inhibit denaturation of the PEG-GM-CSF during lyophilization and rehydration, and optionally a buffer, a tonicifying agent and a preservative. However, a buffer and tonicifying agent may be included in the solution utilized to rehydrate the lyophilized PEG-GM-CSF. A liquid, ready for use, PEG-GM-CSF formulation may include
a stabilizer to inhibit denaturation of the PEG-GM-CSF during storage or when exposed to shear forces, a tonicifying agent, and optionally a buffer and optionally a preservative if the formulation is for multiple uses.
Examples of stabilizers include, sugars, amino acids, organic salts, inorganic salts, diluents, buffering agents, surfactants and preservatives. Stabilizers may further include, human serum albumin, bovine serum albumin and gelatin. Tonicifying agents may include sugars and organic salts. Sugars may include, but are not limited to, monosaccharides such as xylose, mannose, glucose and fructose, disaccharides such as trehalose, lactose, maltose and sucrose, trisaccharides such as raffinose, polysaccharides such as dextran, sugar alcohols such as mannitol, sorbitol and glycerol, and cyclitols such as inositol. Amino acids may include but are not limited to glycine, alanine and lysine. Inorganic salts may include but are not limited to sodium chloride, potassium chloride, calcium chloride, dibasic sodium phosphate, monobasic sodium phosphate potassium phpsphate and sodium hydrogencarbonate. Organic salts include but are not limited to sodium citrate, potassium citrate and sodium acetate. Buffering agents may include, but are not limited to, Tris, phosphate bufferand citrate buffer. Surfactants may include, but are not limited to polysorbate 80 and polysorbate 20. Diluents may include, but are not limited to USP Water for Injection or sterile saline such as phosphate buffered saline. Preservatives may include, but are not limited to, benzyl alcohol, chlorobutanol, methylparaben, propylparaben, phenol, m-cresol, benzalkonium chloride, benzethonium chloride, phenoxyethanol, phenylethyl alcohol, chlorhexidine, benzoic acid, phenylmercuric salts and thimerosal. Use in humans
PEG-GM-CSF may be used in humans for the same indications as GM- CSF for treatment of patients requiring increased proliferation of white blood cells, often with diseases characterized by neutropenias, aberrant blood cell maturation or reduced leukocyte production. An important clinical application of GM-CSF is treatment of neutropenia following chemotherapy, radiation therapy and bone marrow transplantation. Such therapy can help counter related predispositions to infection and hemorrhage. Indications (FDA) include:
• Use following induction chemotherapy in acute myelogenous leukemia
• Use in mobilization and following transplantation of autologous peripheral blood progenitor cells
• Use in myeloid reconstitution after autologous bone marrow transplantation
• Use in myeloid reconstitution after allogenic bone marrow transplantation
• Use in bone marrow transplantation failure or engraftment delay PEG-GM-CSF may be used to enhance tolerance to cytotoxic drugs, such as chemotherapeutic agents, allowing for increased dosing. PEG-GM-CSF may be used to activate resting cancerous cells, making them more susceptible to chemotherapy. PEG-GM-CSF may also be used to treat Crohn's disease, as a vaccine adjuvant (5,679,356), as a treatment for neonatal sepsis, to lower cholesterol levels, as a treatment for radiation exposure, and as a treatment for alveolar proteinosis (6,019,965),
PEG-GM-CSF may be used to modulate host defences against infectious disease, including bacterial/ and fungal infections; it may also be used as an adjunctive agent with treatments for fungal and mycobacterial infections. In the context of the immuno- compromised HIV/AIDS patient, PEG-GM-CSF may be used to combat treatment-related neutropenia, as a prophylaxis and treatment for opportunistic infections, as an enhancer of retroviral treatments, and to reduce HlV expression. PEG-GM-CSF may furthermore be used to modulate host defences for improved anti-tumour or leukemic cell activity. PEG-GM-CSF, including oral and mouthwash formulations, may also be used to treat complications of chemotherapy such as mucositis, stomatitis and diarrhea. Wound healing may be promoted by topical or intradermal PEG-GM-CSF.
The above uses of PEG-GM-CSF in humans may also be considered to include combinations of PEG-GM-CSF with other growth factors that have synergistic effects including but not limited to G-CSF, IL-6, lL-5, IL-3, MMF, SCF, Meg-CSF, IL-4, erythropoietin, IL-1 , IL-2, interferon-alpha, BCDF and TNF. EXAMPLES Abbreviations
AAA, amino acid analysis; AEX, anion-exchange chromatography; ANC, absolute neutrophil count; CE, capillary electrophoresis; HPLC, high-performance liquid chromatography; MALDI-MS, matrix-assisted laser desorption ionization mass spectrometry; NIBSC, National Institute for Biological Standards and Control; PEG, poly(ethylene glycol); PK, pharmacokinetic; RP-HPLC, reversed-phase high-performance liquid chromatography; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SEC, size-exclusion chromatography. Materials Acetonitrile, HPLC grade
Leucotropin™ (Cangene's GM-CSF) DL-lysine Mannitol MiIIi-Q water
20 kDa monomethoxy poly(ethylene glycol)butyraldehyde (mPEG-butyrALD) (Nektar) Prestained Benchmark reduced MW ladder (Invitrogen) Sodium chloride
Sodium cyanoborohydride (Sigma) Sodium phosphate, monobasic Sodium phosphate, dibasic hexahydrate Sodium hydroxide Trifluoroacetic acid (TFA) (Pierce) Source of GM-CSF
LEUCOTROPIN™ (200 mg total) was produced at Cangene Corporation at 2 mg/ml in 10 mM sodium phosphate, 150 mM NaCI pH 7.0. LEUCOTROPIN™ had previously been characterized for identity (Western blot), concentration (A2so), purity (anion exchange, size- exclusion chromatography), and biological potency (TF-1/MTT bioassay; data not shown). LEUCOTROPIN™ was dialyzed using SnakeSkin® dialysis tubing, 3500 MWCO (Pierce Endogen) in 10 mM sodium phosphate buffer, pH 7.0 for 48 h at 4°C prior to conjugation, with buffer changed twice. Source of PEG mPEG butyraldehyde (20,000), mPEG butyraldehyde (30,000), mPEG butyraldehyde (40,000) were purchased from Nektar Therapeutics, San Carlos, CA, US. Description of PEGylation reaction
The conjugation reaction was carried out at 4°C with stirring in 10 mM sodium phosphate buffer, pH 7.0 plus 20 mM sodium cyanoborohydride at a 5:1 mol ratio of 20 kDa PEG-butyraldehyde:protein. Reaction progress was monitored by size-exclusion chromatography. The reaction was quenched with an excess of DL-lysine (Sigma) after 18 hr.
Reaction product was characterized by capillary electrophoresis (CE) on a Beckman P/ACE System 5010 using a 57 cm, 75 μm I.D., 375 μm O. D. eCAP™ silica capillary wound in an eCAP™ capillary cartridge, 100 x 200 urn aperture. Buffer was 100 mM sodium phosphate pH 8.3 run at 8.0 kV; UV absorbance was monitored at 200 nm.
Four peaks were observed with CE (Figure 1), corresponding to non-PEGylated human GM-CSF and human GM-CSF with 1 , 2, or 3 molecules of PEG attached. Purification and Confirmation of Identity of monoPEGylated GM-CSF
Reaction product was dialyzed using SnakeSkin® dialysis tubing, 3500 MWCO (Pierce Endogen) in 20 mM sodium phosphate pH 8.0 for 48 h at 40C, changing buffer twice. The dialyzed PEGylation reaction product was purified on an AKTA Explorer FPLC system equipped with a 20 ml XK 16/10 column packed with Q Sepharose FF resin and a 50 ml Superloop. Elution buffer A was 20 mM sodium phosphate pH 8.0, and Buffer B was 20 mM sodium phosphate pH 8.0 plus 500 mM NaCI. Sample was eluted using a linear AB gradient from 0 to 225 mM NaCI. Fractions were analyzed by SDS-PAGE. Fractions containing only GM-CSF with a single PEG chain per molecule (;.e., monoPEGylated GM-CSF) were pooled and concentrated in Centricon Plus-20 ultracentrifugal filters (Millipore). A buffer exchange of PEG-GM-CSF was conducted by passing 10 mM sodium phosphate, 40 mM NaCI, 30 mg/ml mannitol pH 7.4 through Centricon Plus-20 centrifugal filter devices. The concentration of protein was obtained by measuring absorbance at 280 nm (A2so) and calculated using the molar extinction coefficient of 14180 M"1cm"1 (derived from the amino acid composition of GM-CSF). Sample was diluted to 0.5 mg protein/ml final concentration with 10 mM sodium phosphate, 40 mM NaCI, 30 mg/ml mannitol pH 7.4. PEG-GM-CSF was subjected to a final 0.2 um sterile filtration using a 25 mm HT Tuffryn® syringe filter (Pall Scientific), deposited in 1 ml aliquots into 3 ml sterile borosilicate vials (Comar), stoppered, capped and stored at -800C. A sample from the fill lot was tested for endotoxin levels using the limulus amoebocyte lysate assay and was found to contain less than 25 endotoxin units/ml, indicating that samples were sterile and pyrogen-free.
Final protein concentration of purified monoPEGylated PEG-GM-CSF was determined by UV absorbance at 280 nm and quantitative amino acid analysis on a Beckman 6300 high performance analyzer using System Gold software. Norleucine was added as an internal standard to all samples analyzed by amino acid analysis, and samples were hydrolyzed in 6 N HCI containing 0.1% phenol for 1 hr at 1600C, dried under vacuum and re-dissolved in 200 Dl of running buffer.
Purity of final product was assessed by analytical RP-HPLC (Figure 2), SEC and AEX (not shown). In all cases, chromatograms indicated greater than 95% purity. Reversed-phase HPLC analysis was carried out on an Agilent 1100 liquid chromatograph equipped with a Jupiter C4 column, 250 mm x 2.0 mm i.d., pore size 300 A,
5 urn bead diameter (Phenomenex). Samples were eluted on a linear AB gradient where A = 0.1% trifluoroacetic acid (v/v) in HPLC-grade water and B = 0.1 % trifluoroacetic acid in acetonitrile.
Verification that the final product contained monoPEGylated GM-CSF was accomplished by MALDI-MS (Voyager linear MALDI TOF instrument (Applied Biosystems) with sinapinic acid (SA) matrix.). For the 2OkDa PEG conjugated human GM-CSF, the MALDI-MS data yielded a distribution centering around 36.5 kDa, consistent with the calculated molecular mass of PEG plus human GM-CSF (not shown). Peptide mapping to determine site of monoPEGylation
Both GM-CSF and PEG-GM-CSF were subjected to trypsin digestion and analysis by reversed-phase HPLC to construct peptide maps, in order to determine the site of monoPEGylation. Either GM-CSF or the PEG-GM-CSF conjugate were buffer exchanged to 1 mg/ml protein concentration in 500 mM Tris buffer, pH 8.1. TPCK-trypsin (0.25 mg/ml in 1 mM HCI solution) (Worthington Enzymes) was added for a final 1 :25 ratio (w/w) of enzyme:protein and incubated at 370C in 0.5 M Tris, pH 8.1. Reaction was stopped after 6 hr by boiling samples 5 minutes and reducing in 20 mM dithiothreitol. The digested products were analyzed by RP-HPLC on a Jupiter C4 column, 250 x 2.0 mm Ld., and with MALDI-MS.
Following enzymatic digestion, the site of PEG attachment on PEG-GM- CSF was determined using a combination of reversed-phase HPLC analysis and purification, mass spectrometry, and N-terminal peptide sequencing. Trypsin-digested sample was purified by reversed-phase chromatography and fractions corresponding to peptide peaks were collected and dried in a SpeedVac. One peak appeared in the digested PEG-GM-CSF sample that did not appear in the digested GM-CSF sample (Figure 3). MALDI-MS (QStar XL MALDI qTOF (Applied Biosystems) dihydroxybenzoic acid (DHB) matrix) was used to determine that the new peak had a molecular weight of about 23kDa, which was consistent with it being a PEGylated tryptic peptide fragment of GM-CSF.
The PEGylated peptide peak (obtained from the appropriate RP-HPLC fraction) from the trypsin digest of PEG-GM-CSF was subjected to five cycles of N- terminal Edman sequencing. The obtained amino acid sequence of Pro-Ala-Arg (PAR) in the PEGylated peptide corresponds to residues 2-4 of GM-CSF (data not shown). There are no regions in the sequence of GM-CSF other than at positions 2-4 that contain the PAR sequence, suggesting that PEGylation occurred on the tryptic peptide 1AIa-PrO-AIa-
Arg4 (1APAR4). Since the conjugation chemistry employed is specific to primary amino groups at the conditions used, the APAR peptide would only have a single possible site for PEG attachment, at the alpha-amine on the N-terminus. Because the N-terminus of the APAR peptide is also the N-terminus of the full-length GM-CSF molecule, we conclude that, in the monoPEGylated sample obtained, PEGylation occurred substantially at the N- terminus of the full-length GM-CSF protein sequence.
Assessment of bioactivitv with TF-1/MTT cell proliferation bioassays - (For comparison of 2OkDa PEG-GM-CSF with Leucotropin and NlBSC GM-CSF)
In vitro potency of PEG-GM-CSF relative to Leucotropin™ was determined with two methods, both utilizing the GM-CSF dependent TF- 1 cell line. The MTT reduction method (which is dependent on metabolic enzyme activity for color formation) and a direct cell counting method were employed in the same assay. Two 96-well assay plates were prepared, each containing serial dilutions of 2OkDa PEG-GM-CSF or Leucotropin™ as well as the NIBSC standard rhGM-CSF (88/646). Blank wells containing assay media only were negative controls on the same plate.
Assay media was RPMI-1640 plus 0.001 mg/ml insulin, 0.001 mg/ml transferrin, 0.1 Omol/ml 2-mercaptoethanol, 0.02 mg/ml of gentamicin. Following a 24 hour period of growth factor starvation, TF-1 cells were added to all wells and incubated at a final well concentration of about 2.67X105 cells/ml in a 96-well tissue culture plate for 72 hr at 37 DC, 5% CO2. After 72 h incubation, one duplicate plate received 50 Dl of 4 mg/ml MTT (a tetrazolium salt) per well followed by incubation for 3 hr at 37 GC, 5% CO2. Plates were then centrifuged at 1770 g for 15 minutes, supematants were aspirated and 50 Dl of isopropanol were added to each well. Plates were shaken for 5 minutes and absorbance, which increases with cell proliferation in this assay, was read at 595 nm on a 96-well plate reader. The other duplicate plate was placed on ice to minimize additional cell proliferation, 30 Dl aliquots were removed and added to 30 Dl of Trypan blue stain. Live cells were counted on a hemacytometer to determine live cell concentration from each well.
The log dose-response curve for the 1st International Reference Standard was fit using a four-parameter logistic model and estimates of the curve fit parameters obtained. The upper and lower asymptotes, plus the slope factor were then fixed prior to fitting the remaining sample dose-response curves. From the curve fits, estimates of EC50 (the concentration of growth factor that results in 50% maximum response) were obtained. The ratio of the EC50 value obtained for the Reference standard divided by the EC50
value for each Test Sample gives a relative potency that is then multiplied by the assigned potency of the Reference Standard to obtain a potency estimate for each Test Sample.
Cangene's PEGylated versions of GM-CSF exhibit significantly enhanced potency (5.4- 6.7 fold) over the non-PEGylated Leucotropin and the 1st International Reference Standard. Similar enhancement was seen in both the MTT bioassay and direct cell counting methods for determining cell proliferation. There was no significant difference in measured potency between the 2OkDa, 3OkDa and 4OkDa PEG-GM-CSF.
Table 1 - EC50 values and Potency Estimates -
Pharmacokinetics of PEG-GM-CSF in Rats
Male Sprague-Dawley CD jugular catheterized rats were injected subcutaneously with 5 or 50 micrograms protein/kg body mass of either GM-CSF or 2OkDa, 3OkDa or 4OkDa PEG-GM-CSF (n=5 or 6 rats per group, 23 in total). Blood was withdrawn at 14 time points: pre-dose and at t=0.5, 1 , 2, 4, 6, 8, 10,12, 18, 24, 36, 48, and 72 hr. Samples were centrifuged to separate plasma and the concentrations of GM-CSF in samples were determined by a commercial sandwich-based GM-CSF ELISA kit (Pierce Endogen).
ELISA data from the rat PK study were fitted to depletion curves and the coefficient of determination, elimination rates and half-lives were calculated. (Results in Table 2). Statistical analyses were performed using SAS Release 8.2 for Windows and TableCurve 2D, Version 5.1. To fit the depletion curve, the first-order kinetic equation C=βe'κt was used, where C is the concentration at time t, B is the initial concentration and
K is the elimination rate constant. The half-life, T1Z2, was calculated using the formula T1/2 = 0.693/K. All PEG-GM-CSF molecules had significantly greater T1/2 in rats than non- nPEGylated GM-CSF, at doses of 5 and 50ug/kg.
Pharmacokinetics of PEG-GM-CSF in Monkeys
It is known that rhesus macaques, cyanomolgus monkey and human pk values are comparable, and that Rhesus monkeys have been found to be an excellent model for predicting human pharmacokinetic behavior with rHuGM-CSF (Donahue et al., 1986; Mayer, Lam.Obenaus, Liehl & Besemer, 1987; Nienhuis et al., 1987; StoU, Ball, Burchiel, Robison & Smith, 1987). To assess pharmacokinetics of PEG-GM-CSF in a primate model, four macaques were injected subcutaneously with a single dose of 300ug GM-CSF protein/kg. Blood samples were collected at times 0, 0.25, 0.5, 1 , 2, 4, 6, 10 and 24 hours after injection of PEG-GM-CSF. Concentration of GM-CSF in samples was determined by a commercial sandwich-based GM-CSF ELISA kit (Pierce Endogen).
At 14.6h, the T1/2b of PEG-GM-CSF s.c> in monkeys was significantly longer than reported T1/2b values (ranging from 2-3 hours) for non-PEGylated/non-glycosylated GM- CSF administered subcutaneously in humans.
Ability of PEG-GM-CSF to Raise Absolute Neutrophil Count in Normal and Acutely Irradiated Rhesus Monkeys
In non-irradiated control monkeys, administration of PEG-GM-CSF (300ug protein/kg) increased absolute neutrophil count by a factor of about ten (from 2.3X103 to 2.5X104/Dl), within one day of injection. Neutrophils remained elevated for four days following injection, with a maximal neutrophil count of 3.7X104/Dl observed on Day 3 (fig 5). . "
To demonstrate the in vivo pharmacological effects of PEG-GM-CSF with various sized PEG molecules attached, the effect of administration of 2OkDa, 3OkDa or 4OkDa PEG-GM-CSF on neutrophil count was evaluated in macacques that had received uniform, total body x-irradiation.
Male rhesus monkeys, Macaca mulatta, were given a uniform, bilateral midline tissue radiation dose of 600 cGy, then administered bolus injections of 2OkDa, 3OkDa or 4OkDa PEG-GM-CSF subcutaneously at 300 ug protein/kg body mass dosage at 24 hrs post-irradiation and seven days (-168 hrs) post-irradiation. Negative control data were also collected from ten irradiated monkeys administered supportive care and autologous serum, but not PEG-GM-CSF. Monkeys received daily supportive care
including antibiotics, fresh irradiated whole blood and fluids as needed. Peripheral blood was collected daily for determining blood counts.
Irradiated monkeys administered the 20 kDa PEG-GM-CSF on day 1 and again on day 7 post radiation exposure recovered from neutropenia at about day 11. However, animals treated with the 3OkDa and 40 kDa PEG-GM-CSF demonstrated an ANC recovery comparable to controls that were treated with supportive care only. In irradiated monkeys receiving two 20 kDa PEG-GM-CSF doses, at days 1 and 7 post- irradiation, the rate of neutrophil loss was slowed to 0 from day 3 to 5 (Figure 6, squares), relative to negative control monkeys receiving autologous serum (Figure 6, rectangle). Significant improvement (about 10x increase) in ANC was observed from day 8 to 11 following the second PEG-GM-CSF dosing, on day 7 (Figure 6).
The recovery of animals treated with the 20 kD PEG-GM-CSF is surprising given the concentration of PEG-GM-CSF in the serum. Following the first does, the serum levels of 40 kD PEG-GM-CSF reached about 650,000 pg/ml compared to about 280,000 ρg/ml for the 30 kD PEG-GM-CSF and about 250,000 pg/ml for the 30 kD PEG-GM-CSF (Figure 7). Additionally, the serum levels for the 30 kD and 40 kD PEG-GM-CSF molecule appeared to remain at their peak for about 2 to 3 days after the first injection, whereas the levels of 20 kDa PEG-GM-CSF peaked on the day of injection and rapidly decreased. The fact monkeys treated with 20 kDa PEG-GM-CSF recovered fron neutropenia sooner than the 2OkDa and 3OkDa PEG-GM-CSF treatment groups, despite lower concentrations of 20 kDa PEG-GM-CSF is even more surprising given that the results summarized in Table 2 suggest there is little to no difference in in vitro potency amongst the 2OkDa, 3OkDa and 4OkDa PEG-GM-CSF. Inflammatory Response to PEG-GM-CSF is Reduced with 2OkD PEG-GM-CSF
GM-CSF is a key proinflammatory cytokine. In human patients, reactions at GM-CSF injection sites, such as swelling, redness and tenderness, are common side effects. Subcutaneous injection of GM-CSF or 20, 30, or 4OkDa PEG-GM-CSF resulted in localized inflammation in a primate model of myelosuppression. Surprisingly, while the 2OkDa PEG-GM-CSF produced mild inflammation that was easily treatable with antihistamine (diphenhydramine), the 30 and 40 kDa PEG-GM-CSF molecules caused inflammation that was more severe. The unexpected finding suggests that 2OkDa PEG- GM-CSF is the optimal choice of PEGylated GM-CSF.
Claims
1. A full length, non-glycosylated human GM-CSF polypeptide having a single polyethylene glycol molecule having a molecular weight between about 20 kDa to about 40 kD covalently attached through an amino terminal amino acid.
2. The GM-CSF polypeptide of claim 1 wherein the polyethylene glycol molecule has a molecular weight of about 20 kDa.
3. A method for covalently attaching a single PEG aldehyde molecule having a molecular weight of about 20 kDa to an amino terminal amino acid of a full length, non- glycosylated human GM-CSF polypeptide, the method comprising mixing the PEG aldehyde molecule with the full length, non-glycosylated human GM-CSF at pH of 5 to 7.4 in the presence of a reducing agent.
4. The method of claim 3 wherein the PEG aldehyde is PEG butyraldehyde.
5. A pharmaceutical composition comprising a GM-CSF polypeptide having a single polyethylene glycol molecule covalently attached through an amino terminal amino acid.
6. The use of an adduct of recombinant, non-glycosylated GM-CSF protein and a single PEG molecule conjugated to increase circulating neutrophils in a primate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68643005P | 2005-06-02 | 2005-06-02 | |
US60/686,430 | 2005-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007009208A1 true WO2007009208A1 (en) | 2007-01-25 |
Family
ID=37668373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2006/000885 WO2007009208A1 (en) | 2005-06-02 | 2006-06-02 | Poly(ethylene glocol) modified human gm-csf with increased biological activity |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007009208A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010030366A2 (en) * | 2008-09-11 | 2010-03-18 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
CN106841419A (en) * | 2016-12-29 | 2017-06-13 | 合肥安德生制药有限公司 | A kind of method for quick of poly- peptide |
WO2017214249A3 (en) * | 2016-06-08 | 2018-01-18 | Janssen Biotech, Inc. | Gm-csf variants and methods of use |
WO2021185921A1 (en) * | 2020-03-17 | 2021-09-23 | Drugrecure Aps | Liquid formulation of gm-csf for inhalation |
WO2021222806A1 (en) * | 2020-05-01 | 2021-11-04 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for preventing, detecting, and treating inflammatory bowel disease |
WO2023055378A1 (en) * | 2021-09-30 | 2023-04-06 | Savara Inc. | Methods for the treatment of autoimmune pulmonary alveolar proteinosis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6384195B1 (en) * | 1988-10-20 | 2002-05-07 | Polymasc Pharmaceuticals Plc. | Process for fractionating polyethylene glycol (PEG) —protein adducts and an adduct of PEG and granulocyt-macrophage colony stimulating factor |
WO2004060300A2 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
WO2006019950A2 (en) * | 2004-07-16 | 2006-02-23 | Nektar Therapeutics Al, Corporation | Conjugates of a gm-csf moiety and a polymer |
-
2006
- 2006-06-02 WO PCT/CA2006/000885 patent/WO2007009208A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6384195B1 (en) * | 1988-10-20 | 2002-05-07 | Polymasc Pharmaceuticals Plc. | Process for fractionating polyethylene glycol (PEG) —protein adducts and an adduct of PEG and granulocyt-macrophage colony stimulating factor |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO2004060300A2 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
WO2006019950A2 (en) * | 2004-07-16 | 2006-02-23 | Nektar Therapeutics Al, Corporation | Conjugates of a gm-csf moiety and a polymer |
Non-Patent Citations (4)
Title |
---|
KINSTLER O. ET AL.: "Mono-N-terminal poly(ethylene glycol)-protein conjugates", ADV. DRUG DELIV. REV., vol. 54, no. 4, 2002, pages 477 - 483, XP002332713 * |
KNOSLI C. ET AL.: "Polyethylene Glycol (PEG) Modification of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Enhances Neutrophil Priming Activity but not Colony Stimulating Activity", BR. J. HAEMATOL., vol. 82, no. 4, 1992, pages 654 - 663, XP002138688 * |
MALIK F. ET AL.: "Polyethylene Glycol (PEG)-Modified Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) with Conserved Biological Activity", EXP. HEMATOL., vol. 20, no. 8, 1992, pages 1028 - 1035, XP002138685 * |
SHERMAN M.R. ET AL.: "Conjugation of High-Molecular Weight Poly(ethylene Glycol) to Cytokines: Granulocyte-Macrophage Colony-Stimulating Factors as Model Substrates", ACS SYMPOSIUM SERIES, vol. 680, 1997, pages 155 - 169 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010030366A3 (en) * | 2008-09-11 | 2011-09-01 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US8492503B2 (en) | 2008-09-11 | 2013-07-23 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US9228053B2 (en) | 2008-09-11 | 2016-01-05 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US9579392B2 (en) | 2008-09-11 | 2017-02-28 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US11634540B2 (en) | 2008-09-11 | 2023-04-25 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US9908970B2 (en) | 2008-09-11 | 2018-03-06 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
WO2010030366A2 (en) * | 2008-09-11 | 2010-03-18 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US10759906B2 (en) | 2008-09-11 | 2020-09-01 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US11220575B2 (en) | 2008-09-11 | 2022-01-11 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
US11208450B2 (en) | 2016-06-08 | 2021-12-28 | Janssen Biotech, Inc. | GM-CSF variants and methods of use |
WO2017214249A3 (en) * | 2016-06-08 | 2018-01-18 | Janssen Biotech, Inc. | Gm-csf variants and methods of use |
US10562948B2 (en) | 2016-06-08 | 2020-02-18 | Janssen Biotech, Inc. | GM-CSF variants and methods of use |
CN106841419B (en) * | 2016-12-29 | 2019-08-13 | 合肥安德生制药有限公司 | A kind of rapid detection method of poly- peptide |
CN106841419A (en) * | 2016-12-29 | 2017-06-13 | 合肥安德生制药有限公司 | A kind of method for quick of poly- peptide |
WO2021185921A1 (en) * | 2020-03-17 | 2021-09-23 | Drugrecure Aps | Liquid formulation of gm-csf for inhalation |
CN115297844A (en) * | 2020-03-17 | 2022-11-04 | 德拉格雷丘尔公司 | Liquid formulation of GM-CSF for inhalation |
JP7631358B2 (en) | 2020-03-17 | 2025-02-18 | ドラッグリキュア エーピーエス | Liquid formulations of gm-csf for inhalation - Patents.com |
WO2021222806A1 (en) * | 2020-05-01 | 2021-11-04 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for preventing, detecting, and treating inflammatory bowel disease |
WO2023055378A1 (en) * | 2021-09-30 | 2023-04-06 | Savara Inc. | Methods for the treatment of autoimmune pulmonary alveolar proteinosis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5334347B2 (en) | Chemically modified novel erythropoietin stimulating protein compositions and methods | |
KR100689212B1 (en) | BCS combination | |
EP1613274B1 (en) | Human il-18 substitution mutants and their conjugates | |
JP5350330B2 (en) | N-terminal chemically modified protein compositions and methods | |
EP0401384B1 (en) | Chemically modified granulocyte colony stimulating factor | |
AU2001255256A1 (en) | Chemically modified novel erythropoietin stimulating protein compositions and methods | |
US20060029573A1 (en) | Pegylated interferon alpha-1b | |
CN1167777A (en) | interferon conjugate | |
JP2008535793A (en) | Dipolymer / protein conjugate and preparation method thereof | |
KR101549457B1 (en) | A novel conjugate of granulocyte colony-stimulating factor(g-csf) with polyethylene glycol | |
WO2007009208A1 (en) | Poly(ethylene glocol) modified human gm-csf with increased biological activity | |
JP5363987B2 (en) | Polyethylene glycol-G-CSF conjugate | |
US20070031368A1 (en) | Chemokine conjugates | |
TWI708611B (en) | Compositions and methods for pegylated il-11 | |
EP1834963A1 (en) | Di-polymer protein conjugates and processes for their preparation | |
US20040204566A1 (en) | Chemically-modified G-CSF | |
EP1869079A2 (en) | Di-polymer protein conjugates and processes for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06804617 Country of ref document: EP Kind code of ref document: A1 |